?????? ????????????????????????? ?????????????? ?? ????.Unfit patients even have the choice of venetoclax furthermore obinutuzumab (VO) as frontline therapy. This relies on a phase III trial that compared VO with ClbO in aged/unfit patients.113 VO was outstanding regarding response level and progression-absolutely free survival, and had a comparabl